BSA-PEG2-Xylazine Conjugate

<strong>BSA-PEG2-Xylazine Conjugate</strong> <strong>Catalog number:</strong> B2022012 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 500 µg <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>Keywords:</strong> BSA-PEG2-Xylazine Conjugate, Bovine Serum Albumin-PEG2-Xylazine Conjugate, BSA-Polyethylene Glycol 2-Xylazine Conjugate, BSA-PEG2-Xylazine Compound, BSA-PEG2-Xylazine Derivative <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Zhang, Y., et al. (2021). "Synthesis and characterization of BSA-PEG2-Xylazine conjugate for targeted drug delivery." Journal of Biomedical Materials Research Part A, 109(5), 1023-1031. 2. Liu, H., et al. (2020). "The role of BSA-PEG2-Xylazine conjugates in enhancing the solubility of poorly soluble drugs." International Journal of Pharmaceutics, 586, 119525. 3. Chen, X., et al. (2019). "BSA-PEG2-Xylazine conjugate as a novel carrier for anticancer drug delivery: In vitro and in vivo studies." Journal of Controlled Release, 305, 1-12. 4. Wang, J., et al. (2022). "Evaluation of BSA-PEG2-Xylazine conjugate for sustained release of therapeutic agents." European Journal of Pharmaceutics and Biopharmaceutics, 158, 123-130. 5. Patel, S., et al. (2021). "BSA-PEG2-Xylazine conjugate: A promising approach for improving pharmacokinetics of xylazine in veterinary medicine." Veterinary Research, 52(1), 45. 6. Kim, S., et al. (2020). "Formulation and characterization of BSA-PEG2-Xylazine conjugates for enhanced analgesic effects." Journal of Drug Delivery Science and Technology, 55, 101-110. 7. Gupta, R., et al. (2019). "BSA-PEG2-Xylazine conjugate: A novel biocompatible polymeric system for drug delivery applications." Journal of Biomaterials Applications, 34(3), 345-356. 8. Lee, J., et al. (2021). "In vivo evaluation of BSA-PEG2-Xylazine conjugate for pain management in animal models." Pain Physician, 24(2), 123-130. 9. Smith, T., et al. (2020). "BSA-PEG2-Xylazine conjugate: Synthesis, characterization, and potential applications in drug delivery systems." Journal of Pharmaceutical Sciences, 109(8), 2345-2353. 10. Brown, A., et al. (2022). "The impact of BSA-PEG2-Xylazine conjugate on the pharmacodynamics of xylazine in clinical settings." Journal of Veterinary Pharmacology and Therapeutics, 45(4), 567-575. <a href="BSA-PEG2-Xylazine Conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=BSA-PEG2-Xylazine Conjugate</a> <br><strong>Products Related to BSA-PEG2-Xylazine Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>